Literature DB >> 10887513

Therapeutic implications of the TGF-beta system.

B A Arrick1.   

Abstract

This review considers the various roles of the TGF-beta system in mammary carcinogenesis, tumor progression, and cellular responses to therapeutic measures. The paradigm that has evolved from the work of many investigators suggests that loss of tumor cell responsiveness to the effects of TGF-beta can result in a crucial shift in the net effect of TGF-beta within the context of the tumor-host interaction. Principal elements of host-tumor interactions in which this shift may play out, including immune suppression, angiogenesis, and modification of the surrounding extracellular matrix by tumor cells, are potentially amenable to manipulation. Additional effects of TGF-beta, such as suggested by reports of its ability to alter the drug resistance of tumor cells and the drug sensitivity of normal tissues, suggest that appropriate molecular intervention designed to affect the TGF-beta system might constitute an effective therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 10887513     DOI: 10.1007/BF02017395

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  48 in total

Review 1.  Mechanistic interrelationships between two superfamilies: the steroid/retinoid receptors and transforming growth factor-beta.

Authors:  A B Roberts; M B Sporn
Journal:  Cancer Surv       Date:  1992

2.  Mitotic activity, apoptosis and TRPM-2 mRNA expression in DMBA-induced rat mammary carcinoma treated with anti-estrogen toremifene.

Authors:  R Huovinen; A Wärri; Y Collan
Journal:  Int J Cancer       Date:  1993-10-21       Impact factor: 7.396

3.  Differential regulation of expression of three transforming growth factor beta species in human breast cancer cell lines by estradiol.

Authors:  B A Arrick; M Korc; R Derynck
Journal:  Cancer Res       Date:  1990-01-15       Impact factor: 12.701

4.  Therapeutic manipulation of cytokines: transforming growth factor beta-1 protects mice treated with lethal doses of cytarabine.

Authors:  D F Pierce; R J Coffey
Journal:  Am Surg       Date:  1994-01       Impact factor: 0.688

5.  Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma.

Authors:  B I Dalal; P A Keown; A H Greenberg
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

6.  Drug resistance and gene amplification potential regulated by transforming growth factor beta 1 gene expression.

Authors:  A Huang; H Jin; J A Wright
Journal:  Cancer Res       Date:  1995-04-15       Impact factor: 12.701

7.  Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro.

Authors:  A M Wärri; R L Huovinen; A M Laine; P M Martikainen; P L Härkönen
Journal:  J Natl Cancer Inst       Date:  1993-09-01       Impact factor: 13.506

8.  Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer.

Authors:  S M Gorsch; V A Memoli; T A Stukel; L I Gold; B A Arrick
Journal:  Cancer Res       Date:  1992-12-15       Impact factor: 12.701

9.  Lisofylline inhibits transforming growth factor beta release and enhances trilineage hematopoietic recovery after 5-fluorouracil treatment in mice.

Authors:  E Clarke; G C Rice; R S Weeks; N Jenkins; R Nelson; J A Bianco; J W Singer
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

10.  Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer.

Authors:  L M Wakefield; J J Letterio; T Chen; D Danielpour; R S Allison; L H Pai; A M Denicoff; M H Noone; K H Cowan; J A O'Shaughnessy
Journal:  Clin Cancer Res       Date:  1995-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.